Restoring Function After Botox for Chronic Migraine

Restoring Daily Function After Guideline-Approved Botox Reduces Chronic Migraine Days

Imagine waking up most mornings already calculating how many hours you can stay on your feet before the pounding starts. For active people—warehouse supervisors, gym regulars, nurses, or parents who lift kids and grocery bags—chronic migraine turns ordinary movement into a daily negotiation. Headaches arrive 15 or more days each month, often lasting four hours or longer, and at least eight of those days carry the full migraine picture of throbbing pain, light sensitivity, or nausea. Work shifts are shortened. Recreational lifting stops. Even simple household tasks feel risky because one wrong turn or extra load can trigger the next attack. Guideline-approved Botox (onabotulinumtoxinA) changes that calculation by reducing headache days, creating a window in which the body can safely relearn load tolerance and movement capacity.

Chronic migraine is not the same as occasional severe headaches

Established diagnostic criteria require headache on 15 or more days per month for at least three months, with at least eight of those days meeting migraine features or responding to migraine-specific medication. The U.S. Food and Drug Administration approved onabotulinumtoxinA specifically for prevention in adults who meet this threshold.

The standard protocol, refined through the PREEMPT trials, delivers 155 units (with an optional additional 40 units in a “follow-the-pain” pattern) across 31 injection sites in seven muscle groups of the forehead, temples, back of the head, upper neck, and shoulders. Treatments are spaced every 12 weeks. Clinical data show the largest gains typically appear after the second cycle—roughly 24 weeks—when patients average eight to nine fewer headache days per month than at baseline. That reduction is not merely a diary number; it is the practical difference between spending half the month sidelined and reclaiming consistent days for work, training, and family.

At Injury Medical Clinic PA, the dual-licensed team coordinates this medical step with functional restoration.

Dr. Maria Guadalupe Cardenas, MD, Board Certified in Internal Medicine, provides medical direction and confirms that each patient meets guideline criteria before onabotulinumtoxinA is administered. Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, then layers soft-tissue, chiropractic, and movement-based care that builds on the newly available headache-free days. Because fewer attacks mean less protective guarding and less fear of movement, patients can progress load and range without constantly resetting to zero.

Tracking both sides of recovery keeps the process honest. A simple headache diary records every day with four or more continuous hours of head pain, along with severity, associated symptoms, and acute-medication use. After two full cycles, compare the diary with the baseline. Parallel functional measures capture what the reduced headache burden actually allows:

• Cervical range of motion measured with digital inclinometers in flexion, extension, and rotation.
• Load-tolerance tests such as floor-to-waist lifts, overhead carries, or step-down capacity timed or loaded to the patient’s real job or recreational demands.
• Movement-quality screens that note control during squats, single-leg balance, or repeated reaching.
• Work-simulation tasks—pallet handling, prolonged standing with light load, or gym-style sets—performed on days the diary marks as headache-free.

These paired data points show whether the drop in headache days is translating into usable capacity. A patient who once stopped at 10 pounds for fear of triggering pain may, after the second cycle, complete multiple sets at 25–35 pounds with stable form and no next-day flare. That progression is recorded in the same clinical notes that document the Botox response, giving both the patient and any treating providers a clear timeline.

How Fewer Headache Days Unlock Load and Movement

When headache days fall, the nervous system spends less time in a sensitized state. Cervical muscles no longer hold constant protective tension. Sleep improves. The patient can attend scheduled movement sessions instead of canceling them. In practice, this looks like graded progression: first restoring comfortable neck motion and scapular control on non-headache days, then adding light external load, and finally matching the load to the specific demands of the person’s work or sport. Electroacupuncture and targeted soft-tissue work address residual trigger points in the suboccipital and upper trapezius regions that can still limit endurance even after headache frequency drops. Chiropractic adjustments restore segmental mobility so that the improved range is available for functional tasks rather than remaining theoretical.

Patients set their own functional targets—returning to a full eight-hour shift without mid-day rest, completing a previously abandoned strength-training block, or carrying a child without immediate pain. Because the goals come from the patient, progress is measured against those personal benchmarks rather than a generic chart. The dual-scope notes capture both the medical response to onabotulinumtoxinA and the objective movement gains, creating a single record that supports continued care decisions.

Bioethical Pillars in Practice

Beneficence is served by using the guideline-supported reduction in headache days as the foundation for returning people to the activities they value. The combination of medical direction for onabotulinumtoxinA and hands-on functional therapies works toward root-cause capacity rather than temporary symptom masking. Non-maleficence is honored by favoring a treatment that can reduce reliance on daily oral preventives and by progressing load only when form and symptoms allow; non-invasive options such as electroacupuncture and chiropractic adjustments avoid the risks of escalating medication or unnecessary procedures. Autonomy is central: the patient owns the headache diary, chooses the functional goals that matter most, and reviews the paired data with the team so that every next step is an informed choice rather than a directive.

What Makes This Clinic Distinct in El Paso

Injury Medical Clinic PA is the only integrated clinic in El Paso, Texas, that pairs a medical director—Dr. Maria Guadalupe Cardenas, MD, with more than 40 years of internal medicine experience—with a dual-licensed nurse practitioner who specializes in soft-tissue injury. Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, holds Texas License #1191402 and Prescriptive Authority #59628. Together, they coordinate advanced IV protocols, regenerative options, acupuncture, electroacupuncture, and precise functional-movement testing under one roof. This structure links headache-day reduction from guideline-approved Botox to measurable gains in load tolerance and movement capacity, all documented in Colossus-compliant notes that remain useful for both clinical care and any related medical-legal needs.

For readers exploring related topics, the complete clinical guide to integrated migraine care is available at the Integrated Migraine Treatment resource on dralexjimenez.com. The Causation Insights resource discusses how cervical findings interact with headache causation, while the Rehabilitation Exercises guide outlines step-by-step rehabilitation progressions after head and neck injury. The master reference for establishing medical-legal causation across personal-injury cases sits at https://dralexjimenez.com.

Functional outcome tracking complements establishing medical-legal causation in personal injury at https://dralexjimenez.com.

If frequent migraine days are limiting the work or training you want to do, the coordinated team can review your headache pattern against established criteria and map a plan that pairs guideline-approved preventive treatment with progressive functional restoration. Contact Injury Medical Clinic PA in El Paso to schedule an evaluation and begin rebuilding the capacity that headache days have taken away.

---

References

Headache Classification Committee of the International Headache Society (IHS). (2018). The International Classification of Headache Disorders, 3rd edition. Cephalalgia, 38(1), 1–211. https://doi.org/10.1177/0333102417738202

Aurora, S. K., Dodick, D. W., Turkel, C. C., DeGryse, R. E., Silberstein, S. D., Lipton, R. B., Diener, H. C., & Brin, M. F. (2010). OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia, 30(7), 793–803. https://doi.org/10.1177/0333102410364676

Aurora, S. K., Winner, P., Freeman, M. C., Spierings, E. L., Heiring, J. O., DeGryse, R. E., VanDenburgh, A. M., Nolan, M. E., & Turkel, C. C. (2011). OnabotulinumtoxinA for treatment of chronic migraine: Pooled analyses of the 56-week PREEMPT clinical program. Headache, 51(9), 1358–1373. https://doi.org/10.1111/j.1526-4610.2011.01990.x

U.S. Food and Drug Administration. (2010, October 15). FDA approves Botox to treat chronic migraine. U.S. Department of Health and Human Services.

Potrebic, S., Tanveer, S., Becker, W. J., Burch, R., Cooke, L. J., Fenton, T., Fletcher, J. J., Gordon Perue, G. L., Hershey, A. D., Jackson, J. L., Kessel, S., Loder, E. W., Minen, M. T., Oskoui, M., Ramanan, V. K., Murren, M., Schwedt, T. J., Silberstein, S. D., Smith, D. B., … Pringsheim, T. (2026). Pharmacologic treatment for migraine prevention in adults: Practice guideline recommendations. Headache, 66(9), 2173–2184. https://doi.org/10.1111/head.70199

Pringsheim, T., Smith, D. B., Tanveer, S., Becker, W. J., Burch, R., Cooke, L. J., … Potrebic, S. (2026). Systematic review of pharmacologic treatment for migraine prevention in adults: Report of the AAN Guidelines Subcommittee and the American Headache Society. Neurology, 107(7), e218112. https://doi.org/10.1212/WNL.0000000000218112